Incyte Corporation - Common Stock (NQ:INCY)

115.30 -1.84 (-1.57%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

29 30 Next >

Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers

August 17, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers.

Via StockStory

Topics Artificial Intelligence

Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy Lawsuit

INCY Q2 Deep Dive: Product Launches and Pipeline Progress Underpin Revenue Growth

August 13, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 16.5% year on year to $1.22 billion. Its non-GAAP profit of...

Via StockStory

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer ↗

August 01, 2025

Via Stocktwits

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

A Look at Incyte's Upcoming Earnings Report ↗

July 28, 2025

Via Benzinga

1 Momentum Stock for Long-Term Investors and 2 Facing Challenges

August 11, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media...

Via StockStory

Beyond The Numbers: 12 Analysts Discuss Incyte Stock ↗

August 06, 2025

Via Benzinga

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

August 05, 2025

From Incyte

Via Business Wire

Incyte Corp (NASDAQ:INCY): A Value Investing Gem with Strong Valuation and Financial Stability ↗

August 04, 2025

Incyte Corp (INCY) is a value investor's pick with a strong 9/10 Valuation Rating, low P/E ratios, solid financial health, and steady profitability in biotech.

Via Chartmill

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? ↗

August 04, 2025

The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria.

Via Investor's Business Daily

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday ↗

August 01, 2025

Via Benzinga

The Analyst Verdict: Incyte In The Eyes Of 10 Experts ↗

July 30, 2025

Via Benzinga

Top S&P500 movers in Tuesday's session ↗

July 29, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.

Via Chartmill

Incyte (INCY) Stock Trades Up, Here Is Why

July 29, 2025

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 10.4% in the afternoon session after the company reported second-quarter financial results that beat analyst expectations and...

Via StockStory

Topics Artificial Intelligence

Uncover the latest developments among S&P500 stocks in today's session. ↗

July 29, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand ↗

July 29, 2025

Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.

Via Benzinga

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday? ↗

July 29, 2025

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

Via Benzinga

Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday ↗

July 29, 2025

Via Benzinga

Which S&P500 stocks are moving before the opening bell on Tuesday? ↗

July 29, 2025

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.

Via Chartmill

Incyte (NASDAQ:INCY) Reports Strong Q2

July 29, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q2 CY2025, with sales up 16.5% year on year to $1.22 billion. Its non-GAAP profit of $1.57 per share...

Via StockStory

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

July 29, 2025

From Incyte

Via Business Wire

Incyte (INCY) Q2 Earnings: What To Expect

July 27, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be announcing earnings results this Tuesday morning. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

July 24, 2025

From Incyte

Via Business Wire

1 Value Stock Worth Your Attention and 2 Facing Headwinds

July 24, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Topics Supply Chain

INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Attractive Valuation ↗

July 12, 2025

INCYTE CORP (NASDAQ:INCY) presents a value opportunity with strong profitability, financial health, and an undervalued forward P/E. Analysts expect earnings growth despite a slight revenue decline.

Via Chartmill

Incyte to Report Second Quarter Financial Results

July 10, 2025

From Incyte

Via Business Wire

3 Cash-Producing Stocks with Questionable Fundamentals

July 08, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

3 S&P 500 Stocks Skating on Thin Ice

July 03, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 02, 2025

From Incyte Corporation

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.